Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | HAE | Common Stock | Award | +587 | +105.39% | 1.14K | May 17, 2024 | Direct | F1, F2, F3 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | HAE | Non-qualified Stock Option (Right to Buy) | Award | $0 | +1.29K | $0.00 | 1.29K | May 17, 2024 | Common Stock | 1.29K | $95.73 | Direct | F4 |
Id | Content |
---|---|
F1 | The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. |
F2 | Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. |
F3 | This number includes unvested RSUs previously reported. |
F4 | Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. |